CTOs on the Move

Vigil Neuroscience

www.vigilneuro.com

 
Vigil Neuroscience is the world`s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain`s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vigilneuro.com
  • One Broadway Suite 07-300
    Cambridge, MA USA 02142
  • Phone: 857.254.4445

Executives

Name Title Contact Details

Funding

Vigil Neuroscience raised $50M on 12/08/2020

Similar Companies

Concept Matrix Solutions

Concept Matrix Solutions is a company that specializes in the formulation, development, and manufacturing of novel drug delivery systems utilizing CBD from Industrial Hemp and other cannabinoids, as well as Nutraceuticals. They also provide the highest...

Wallace Pharmaceuticals

Wallace Pharmaceuticals is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.

Meridian Behavioral Healthcare,

Serving North Central Florida, covering a geographic area of almost 7,500 square miles that is largely rural and sparsely populated, serving the following 12 counties: Alachua, Baker, Bradford, Columbia, Dixie, Gilchrist, Hamilton, Lafayette, Levy, Put...

Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.